Drug interaction study aims to unlock safer dosing for new lung therapy
NCT ID NCT07696091
First seen Jul 10, 2026 · Last updated Jul 10, 2026
Summary
This study examines how the antibiotics rifampicin and clarithromycin change the way the body processes an experimental drug called RSS0343. RSS0343 is being developed for chronic lung and sinus diseases like bronchiectasis and COPD. The trial enrolls 40 healthy adults aged 18 to 55 to measure drug levels and safety, helping researchers understand how to adjust dosing when these medications are used together.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RSS0343 tablet, rifampicin capsules, clarithromycin tablets
- What this could lead to
- If successful, this study will help determine the right dose of RSS0343 when taken with other common drugs, potentially improving treatment for lung and sinus conditions.
- What could go wrong
- This is an early-phase study in healthy volunteers, not patients. Results may not predict effects in people with the target diseases, and drug interactions could increase side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-CYSTIC FIBROSIS BRONCHIECTASIS、CHRONIC SINUSITIS WITHOUT NASAL POLYPS、CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Guangzhou, Guangdong, 510405, China
Contact
Contact